HonorHealth Research Institute

Summary

HonorHealth Research Institute is a medical facility located in Scottsdale, Arizona. This center is recognized for care of Pancreatic Cancer, Solid Tumors, Cancer, Lung Cancer, Ovarian Cancer and other specialties. HonorHealth Research Institute is involved with conducting 152 clinical trials across 253 conditions. There are 14 research doctors associated with this hospital, such as Vincent Chung, MD, Michael S Gordon, MD, Sunil Sharma, and Erkut Borazanci, MD.

Top PIs

Clinical Trials running at HonorHealth Research Institute

Pancreatic Cancer

Lung Cancer

Solid Tumors

Colorectal Cancer

Breast Cancer

Melanoma

Non-Small Cell Lung Cancer

Cancer

Ovarian Cancer

Non-Hodgkin's Lymphoma

RAS(ON) Inhibitors

for Gastrointestinal Cancer

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current subprotocols include the following: Subprotocol A: RMC-6236 + 5-fluorouracil-based regimens Subprotocol B: RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol C: RMC-6236 + gemcitabine + nab-paclitaxel Subprotocol D: RMC-9805 with or without RMC-6236 + 5-fluorouracil-based regimens Subprotocol E: RMC-9805 with or without RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol F: RMC-9805 with or without RMC-6236 + gemcitabine + nab-paclitaxel

Recruiting

1 award

Phase 1 & 2

4 criteria

Early Detection

for Pancreatic Cancer

This study evaluates individuals without pancreatic cancer, but who have been determined to be at higher-than-average lifetime risk of developing pancreatic cancer to help detect pancreatic cancer or other cancers at an earlier time when they might be more easily treated and cured.

Recruiting

1 award

N/A

10 criteria

CLSP-1025

for Cancer

Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A\*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

Recruiting

1 award

Phase 1

6 criteria